Exercise/NAD+ study

Research clinicians at the Children’s Hospital of Philadelphia and University of Pennsylvania are enrolling participants in a study to evaluate the effects of a dietary supplement combined with exercise. The primary outcome measure is changes in aerobic capacity, which is the body’s ability to take in, transport and use oxygen during exercise.

This study will be enrolling over 4 years, starting in 2020, with a target enrollment of 72 participants. Compensation is provided for study time.

Eligibility criteria include:

  • Genetically-confirmed diagnosis of FA
  • Age 10-40 years old
  • Able to complete exercise testing
Participation is this study involves completion of two (2) in-person clinic visits, each lasting 2 days, over a 12-week period. During the study period, you will be asked to complete blood testing, exercise testing, administration of a dietary supplement, MRI scans, oral glucose tolerance testing (with a non-FDA approved stable isotope product) and optional muscle biopsies.

If you are interested in learning more about this study, please contact Anna DeDio through email This email address is being protected from spambots. You need JavaScript enabled to view it. or by phone (267)-425-1998.

Anyone considering participating in a clinical trial should discuss the matter with his or her physician. FARA does not endorse or recommend any particular studies.